(Updated) 2013 ASCO: abstracts

[Maia]

Abstracts of that to be presented at the 2013 (May 31- June 4) ASCO Annual Meeting, for CRC, can be read online here:
http://abstracts2.asco.org/CatAbstView_132_175_AA.html


Updated June 1st 2013: Abstracts for Colorectal cancer here

[some]

Thanks Maia. Much appreciated. I read like 50 of the abstracts and conclusions. I get the gist of it. Faster with the breakthroughs please!!!

[Maia]

Updating:
June 1st 2013: Abstracts for Colorectal cancer here

[gep]

Thanks Maia.
I looked through them. PDL1 single agent trial is closed to colon cancer, by the way.
Gloria

[Maia]

I know, and I have to wonder why. I mean, they have some sort of result even in some of these without the marker (the protein). In comparison, how is that something like regorafenib got approved with the OS numbers that it has, and with *that* side effect profile, that is beyond me.
Still, it could be one of those cases when it works better with other agent, and not as monotherapy. I feel there are many missed opportunities, because companies want THE big bullet. What if the answer is the 'magic' combination? It looks like that is what is working best, for several out there...
Sorry, digressing!

[dianne052506]

Gloria,
The MPDL3280A dual agent study now says "not yet recruiting" for TN. http://clinicaltrials.gov/ct2/show/NCT01633970
I don't believe they offered it at all there before because I remember Dr. P saying he was the only one in the Southeast who had it. Is there any possibility of getting DH into the MPDL3280A/Avastin arm in Nashville? If I understood Dr. P. correctly this week, he expects a few more of those slots to open this summer. He pretty much implied that to be considered at CBO, he would want a face-to-face first, and I realize you are a long way from NC. Since you've already been seen at Nashville, have you asked them about being first in line there?
I must admit to still dealing with anger issues that the drug that is keeping me stable has not been available to friends here. I just want something to work out.
Dianne

[dianne052506]

Maia,
Again, thanks so much for all the time and trouble you put into this. Your knowledge is amazing. And do I remember reading that you don't believe your English is that good? Trust me, you are far easier to understand than some of these abstracts!
Dianne

[Maia]

LOL Dianne!

Gloria have you checked this trial in Chicago with the other anti-PD1 (Bristol-Meyers) and other agent? http://clinicaltrials.gov/show/NCT01714739
BMS-936558 (MDX-1106) is now called Nivolumab, got best results in melanoma (ASCO 2013)

Just in case, disregard if the inclusion/exclusion criteria don't fit.

[gep]

Dianne and Maia,
Eli had a chance at your trial at Georgetown. It took two sets of tumor tissue and 5 weeks to learn that his tumor did not express the PDL1 so he can't be in the trial. We've spoken to the nurse practitioner at Sarah Cannon in Nashville and they are about to have the trial there with all three arms in addition to the single agent trial. The problem is that he doesn't qualify. Sarah Cannon is offering him a slot in a QTC (some kind of heart study) study of TAS 102 as of July 1. He has to wait four more weeks which is not easy as he's been having major gastric issues probably compounded by his abdominal lymph node metastasis. Endoscopy done two weeks ago was clear.
The trial at the U of Chicago has an enormous waiting list already for very few slots. I also checked out another new immunotherapy trial with a different BMS (I think) drug in Indianapolis but that drug hasn't been used much and there's no info on colon cancer that I know of. If anyone knows more about that one, let me know. That waiting list is not as long.
Very anxious but still hanging in there.
Gloria

here's the link: http://clinicaltrials.gov/show/NCT01471210

[Maia]

Gloria, sent you a PM : )

[Maia]

Gloria, just wanted to mention that the University of Chicago is exploring a similar (maybe the same?) protocol than Dr Lin (U. of Washington, Seattle): 'just' capecitabine and celecoxib (that is, Xeloda and Celebrex). I know first hand, because of my friend, the hate of IV chemotherapy, hospital visits... these are two oral agents (and the Celebrex prevents the Xeloda induced hand-foot syndrome). The safety profile is high, little of 'experimental' agent here... just putting it out there for you, it's just around the corner (only at the University of Chicago): http://clinicaltrials.gov/ct2/show/NCT01705106

"This clinical trial studies capecitabine and celecoxib in treating patients with solid malignancies that are metastatic or cannot be removed by surgery. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving capecitabine and celecoxib together may be an effective treatment for solid malignancies."

Or this one: WT2725, a WT1 peptide vaccine: http://clinicaltrials.gov/show/NCT01621542 WT1 is a good target for colon cancer (http://www.ncbi.nlm.nih.gov/pubmed/14961577). Injections every 1 or 4 weeks, it has good data from Japan. University of Chicago also.

[gep]

Maia,
Thanks so much for the updated info. He developed an allergy to NSAIDS. I have read that an allergy to Advil or Aleve does not necessarily mean an allergy to celebrex but he'd have to be tested. He went for a second opinion to U of C at one point. I think he should maybe go there for another visit. We live in the City so it's not such a big deal as taking a plane.
Thanks again, Maia.
Gloria

[concernedrelative]

Glomming on to ASCO news, blog post from Genentech reviewing resistance and what they are doing about it generally (30 trials).

http://www.gene.com/asco/resistance-is-not-futile

Another one by another of their researchers on immunotherapy--

http://www.gene.com/asco/immunotherapy-100-years-new

HTH, Concerned Relative

[concernedrelative]

For those looking for a deep science wrap up of findings from the conference, here is link to peer reviewed journal Clinical Advances in Hematology & Oncology

http://www.hematologyandoncology.net/fi ... _sup83.pdf